Serum homocysteine, cholesterol, retinol, α-tocopherol, glycosylated hemoglobin and inflammatory response during therapy with bevacizumab, oxaliplatin, 5-fluorouracil and leucovorin

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4813-4820

  Melichar, Bohuslav ^a,b   Kalábová, Hana ^a   Krčmová, Lenka ^a   Kašparová, Markéta ^a   Malířová, Eva ^a   Melicharová, Karolina ^a   Pecka, Miroslav ^a   Hyšpler, Radomír ^a   Solichová, Dagmar ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Bevacizumab; Homocysteine; Metastatic colorectal carcinoma

Indexed keywords

ALPHA TOCOPHEROL; BEVACIZUMAB; C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; CHOLESTEROL; DEXAMETHASONE; FERRITIN; FLUOROURACIL; FOLINIC ACID; GLYCOSYLATED HEMOGLOBIN; GRANISETRON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ONDANSETRON; OXALIPLATIN; RETINOL;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; INFLAMMATION; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; TREATMENT RESPONSE;

EID: 75149138791     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Grothey A, Sargent D, Goldberg RM and Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209-1214, 2004.
2. Hurwitz H, Febrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, E. H, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004.
3. Cunningham D, Hurnblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004.
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000.
5. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 78: 2938-2947, 2000.
6. Giantonio BJ, Catalano PJ, Meropol NJ, ODwyer PJ, Mitchell EP, Alberts SR and Schwartz MA: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 25: 1539-1544, 2007.
7. Mourad JJ, des Guetz G, Debbabi H and Levy BI: Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 19: 927-934, 2008.
8. Adam R, Wicherts DA, de Haas RJ, Ciacio O, Levi F, Paule B, Ducreux M, Azoulay D, Bismuth H and Castaing D: Patients with initially unresectable colorectal liver metastases: Is there a possibility of cure? J Clin Oncol 27: 1829-1835, 2009.
9. Ridker PM: Novel risk factors and markers for coronary disease. Adv Intern Med 45: 391-419, 2000.
10. Nabholtz JM and Gligorov J: Cardiovascular safety profiles of aromatase inhibitors. A comparative review. Drag Saf 29: 785-801, 2006.
11. Esteva FJ and Hortobagyi GN: Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. Breast 15: 301-312, 2006.
12. Sarwar AB, Sarwar A, Rosen BD and Nasir K: Measuring subclinical atherosclerosis: is homocysteine relevant? Clin Chem Lab Med 45: 1667-1677, 2007.
13. Wierzbicki AS: Homocysteine and cardiovascular disease: A review of the evidence. Diab Vase Dis Res 4: 143-149, 2007.
14. Schroecksnadel K, Frick B, Fiegl M, Winkler C, Denz HA and Fuchs D: Hyperhomocysteinamia and immune activation in patients with cancer. Clin Chem Lab Med 45: 47-53, 2007.
15. Sun CF, Haven TR, Wu TL, Tsao KC and Wu JT: Serum total homocysteine increases with me rapid proliferation rate of tumor cells and declines upon cell death: a potential new tumor marker. Clin Chim Acta 321: 55-62, 2002.
16. Wu LL and Wu JT: Hyperhomocysteinemia is risk factor for cancer and a new potential tumor marker. Clin Chim Acta 322: 21-28, 2002.
17. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H and Nordestgaard BG: Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359: 1897-1908, 2008.
18. Ridker PM, Hennekens CH, Buring JE and Rifai N: C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342: 836-843, 2000.
19. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ and Rimm EB: Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351: 2599-2610, 2004.
20. Steinberg D: Oxidative modification of LDL and atherogenesis. Circulation 95: 1062-1071, 1997.
21. Keaney JF, Guo Y, Cunningham D, Swaery GT, Xu A and Vita JA: Vascular incorporation of alpha-tocopherol endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation. J Clin Invest 98: 386-394, 1996.
22. Salonen JT, Nyyssonen K, Salonen R, Lakka H-M, Kaikkonen J, Porkkala-Sarataho E, Voutillainen S, Lakka TA, Rissanen T, Leskinen L, Tuomainen T-P, Valkonen V-P, Ristonmaa U and Poulsen HE: Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: randomized trial of the effect of vitamins E and C on 3-year progession of carotid atherosclerosis. J Intern Med 248: 377-386, 2000.
23. Debier C and Larondelle Y: Vitamins A and E: metabolism, roles and transfer to offspring. Br J Nutr 93: 153-174, 2005.
24. Delanian S, Porcher R, Balla-Mekias S and Lefaix JL: Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol 21: 2545-2550, 2003.
25. Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G, Biroccio A, Leonetti C, Jandolo B, Cognetti F and Bove L: Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 21: 927-931, 2003.
26. Faure H, Coudray C, Mousseau M, Ducros V, Douki T, Bianchini F, Cadet J and Favier A: 5-Hydroxymethyluracil excretion, plasma TBARS and plasma antioxidant vitamins in adriamycin-treated patients. Free Rad Biol Med 20: 979-983, 1996.
27. Jonas RC, Puckett AB, Jones DP, Griffith DP, Szeszycki EE, Bergman GF, Furr CE, Tyre C, Carlson JL, Galloway JR, Blumberg JB and Ziegler TR: Plasma antioxidant status after highdose chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients. Am J Clin Nutr 72: 181-189, 2000.
28. High KP, Legault C, Sinclair JA, Cruz J, Hill K and Hurd DD: Low plasma concentrations of retinol and alpha-tocopherol in hematopoietic stem cell transplant recipients: the effect of mucositis and the risk of infection. Am J Clin Nutr 76: 1358-1366, 2002.
29. Faber M, Coudray C, Hida H, Mousseau M and Favier A: Lipid peroxidation products, and vitamin and trace element status in patients with cancer before and after chemotherapy, including adriamycin. A preliminary study. Biol Trace Elem Res 47: 117-123, 1995.
30. Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R and Salonen R: High stored iron levels are associated with excess risk of myocardial infarction in Eastern Finnish men. Circulation 86: 803-811, 1992.
31. Tuomainen TP, Punnonen K, Nyyssonen K and Salonen JT: Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 97: 1461-1466, 1998.
32. Melichar B, Urbanek L, Krcmova L, Kalabova H, Melicharova K, Malirova E, Hornychova H, Ryska A, Hyspier R and Solichova D: Urinary neopterin, hemoglobin and peripheral blood cell counts in breast carcinoma patients treated with dose-dense chemotherapy. Anticancer Res 28: 2389-2396, 2008.
33. Urbanek L, Solichova D, Melichar B, Dvorak J, Svobodova I and Solich P: Optimization and validation of a high-performance liquid chromatography method for the simultaneous determination of vitamins A and E human serum using monolithic column and diode-array detection. Anal Chim Acta 573-574: 267-272, 2006.
34. Hoelzel W, Weykamp C, Jeppesson JO, Miedema K, Barr JR, Goodall I, Hoshino T, John WG, Kobold U, Little R, Mosca A, Mauri P, Paroni R, Susanto F, Takei I, Thienpont L, Umemoto M and Weidmeyer HM: IFCC reference system for measurement of hemoglobin A, in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 50: 166-174, 2004.
35. Melichar B, Solichova D, Melicharova K, Malirova E, Cermanova M and Zadak Z: Urinary neopterin in patients with advanced colorectal carcinoma. Int J Biol Markers 21: 190-198, 2006.
36. Banerjee S, Smith IE, Folkerd L, Iqbal J, Barker P and Dowset M: Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. Ann Oncol 16: 1632-1638, 2005.
37. Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C and Topolcan O: Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 39: 718-727, 2003.
38. Sorbye H and Dahl O: Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncol 43: 495-498, 2004.
39. Ailawadhi S, Sunga A, Rajput A, Yang GY, Smith J and Fakih M: Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. Oncology 70: 49-53, 2006.
40. Melichar B, Jandik P, Tichy M, Malir F, Mergancova J and Voboril Z: Urinary zinc excretion and acute phase response in cancer patients. Clin Investig 72: 1012-1014, 1994.
41. Gori AM, Sofi F, Marcucci R, Giusti B, Franco Gensini G and Abbate R: Association between homocysteine, vitamin B6 concentrations and inflammation. Clin Chem Lab Med 45: 1728-1736, 2007.
42. Ridker PM, Rifai N, Rose L, Buring JE and Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565, 2002.
43. Sartori S, Nielsen I, Masotti M and Malacarne P: Early and late hyperferremia during cisplatin chemotherapy. J Chemother 5: 45-50, 1991.
44. Pollera CF, Ameglio F, Nardi M, Marolla P, Carlini P and Frasca AM: Dose and schedule effects of cisplatin on the related acute iron changes. Oncology 47: 133-138, 1990.
45. Pollera CF, Ameglio F, Reina S, Nardi M, Abbolito MR and Parracino C: Changes in serum iron levels following very high dose cisplatin. Cancer Chemother Pharmacol 19: 257-260, 1987.
46. Lauterburg BH, Nguyen T, Hartmann B, Junker E, Kupfer A and Cerny T: Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol 35: 132-136, 1994.
47. Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D, Hudson M, Rubnitz J, Sandlund JT, Pui CH and Relling MV: Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 21: 3084-3091, 2003.
48. Geisler J, Geisler SB, Lonning PE, Smaaland R, Tveit KM, Refsum H and Ueland PM: Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients. Clin Cancer Res 4: 2089-2093, 1998.
49. Slater GH, Ren CJ, Siegel N, Williams T, Barr D, Wolfe B, Dolan K and Fielding GA: Serum fat-soluble vitamin deficiency and abnormal calcium metabolism after malabsorptive bariatric surgery. J Gastrointest Surg 8: 48-55, 2004.
50. Johnson EJ, Krasinski SD, Howard LJ, Alger SA, Dutta SK and Russell RM: Evaluation of vitamin A absorption by using oil-soluble and water-miscible vitamin A preparations in normal adults and in patients with gastrointestinal disease. Am J Clin Nutr 55: 857-864, 1992.
51. Melichar B, Dvorak J, Krcmova L, Hyspler R, Urbanek L and Solichova D: Intestinal permeability and vitamin A absoption in patients with chemotherapy-induced diarrhea. Am J Clin Oncol 31: 580-584, 2008.
52. Melichar B, Kalabova H, Krcmova L, Urbánek L, Hyspler R, Malirova E and Solichova D: Serum alpha-tocopherol, retinol and neopterin during paclitaxel/carboplatin chemotherapy. Anticancer Res 27: 4397-4401, 2007.
53. McMillan DC, Talwar D, Sattar N, Underwood M, O'Reilly DSJ and McArdle C: The relationship between reduced vitamin antioxidant concentrations and the systemic inflammatory response in patients with common solid tumours. Clin Nutr 21: 161-164, 2002.
54. McMillan DC, Sattar N, Talwar D, O'Reilly J and McArdle CS: Changes in micronutrient concentrations following anti-inflammatory treatment in patients with gastrointestinal cancer. Nutrition 16: 425-428, 2000.
55. Mayland C, Allen KR, Degg TJ and Bennet M: Micronutrient concentrations in patients with malignant disease: effect of the inflammatory response. Ann Clin Biochem 47: 138-141, 2004.
56. Kennedy DD, Tucker KL, Ladas ED, Reingold SR, Blumberg J and Kelly M: Low antioxidant vitamin intakes are associated with increases in adverse effects of chemotherapy in children with acute lymphoblastic leukemia. Am J Clin Nutr 79: 1029-1036, 2004.
57. Chiarelli F, Spagnolit A, Basciani F, Tumini S, Mezzetti A, Cipollone F, Cuccurullo F, Morgese G and Verrotti A: Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: relation to glycaemic control and microvascular complications. Diabet Med 77: 650-656, 2000.
58. Lim HS, Blann AD, Chong AY, Freestone B and Lip GYH: Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes. Diabetes Care 27: 2918-2924, 2004.
59. Kakizawa H, Itoh M, Itoh Y, Imamura S, Ishiwata Y, Matsumoto T, Yamamoto K, Kato T, Ono Y, Nagata M, Hayakawa N, Suzuki A, Goto Y and Oda N: The relationship between glycemic control and plasma vascular endothelial growth factor and endothelin-1 concentration in diabetic patients. Metabolism 53: 550-555, 2004.
60. Hillege HL, Fidler V, Diercks GFH, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans ROB, Janssen WMT, Grobbee DE and de Jong PE: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106: 1777-1782, 2002.
61. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J and Dearnley DP: Cardiovascular disease as a longterm complication of treatment for testicular cancer. J Clin Oncol 21: 1513-1523, 2003.
62. Meinardi MT, Gietema JA, van der Graaf WTA, van Veldhuisen DJ, Runne MA, Sluiter WJ, de Vries EGE, Willemse PBH, Mulder NH, van den Berg MP, Scharffordt Koops H and Sleijfer DT: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18: 1725-1732, 2000.
63. Zagars G K., Ballo MT, Lee AK and Strom SS: Mortality after cure of testicular seminoma. J Clin Oncol 22: 640-647, 2004.
64. Tournigand C, Andre T, Achille E, Lledo G, Flesch M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237, 2004.